Detalles de la búsqueda
1.
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
Oncology
; 102(3): 271-282, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37725914
2.
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.
Int J Clin Oncol
; 29(2): 124-133, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38160406
3.
[Thoracic SMARCA4-deficient undifferentiated tumor resembling malignant lymphoma].
Rinsho Ketsueki
; 64(4): 271-276, 2023.
Artículo
en Japonés
| MEDLINE | ID: mdl-37121771
4.
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Invest New Drugs
; 40(5): 1066-1079, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35749041
5.
Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1.
BMC Cancer
; 22(1): 1325, 2022 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528575
6.
Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy.
Oncology
; 99(9): 562-570, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34237736
7.
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
BMC Cancer
; 21(1): 208, 2021 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33648453
8.
Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma.
Chemotherapy
; 66(3): 65-71, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827084
9.
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.
Medicina (Kaunas)
; 57(11)2021 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34833490
10.
Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.
Jpn J Clin Oncol
; 50(8): 909-919, 2020 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32548617
11.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol
; 20(5): 625-635, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975627
12.
Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Cancer Sci
; 110(12): 3738-3745, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31608537
13.
Small cell lung carcinoma initially presenting as giant left ventricular mass.
Jpn J Clin Oncol
; 54(3): 359-360, 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38088026
14.
Detection of pseudoprogression with [18F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment.
Eur J Nucl Med Mol Imaging
; 48(4): 1268-1270, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33094431
15.
[Hange-Shashin-to for preventing diarrhea during afatinib therapy].
Gan To Kagaku Ryoho
; 42(5): 581-3, 2015 May.
Artículo
en Japonés
| MEDLINE | ID: mdl-25981651
16.
Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab.
Ann Hematol
; 98(12): 2851-2852, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31734737
17.
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in nonsmall cell lung cancer treated with immunotherapy.
Oncol Lett
; 27(3): 110, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38304175
18.
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.
Cancers (Basel)
; 16(7)2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611087
19.
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Thorac Cancer
; 15(2): 163-171, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38013668
20.
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
JTO Clin Res Rep
; 5(4): 100655, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38706978